David Vicente Baz

1.3k total citations
27 papers, 235 citations indexed

About

David Vicente Baz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, David Vicente Baz has authored 27 papers receiving a total of 235 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 4 papers in Immunology. Recurrent topics in David Vicente Baz's work include Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (9 papers). David Vicente Baz is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (9 papers). David Vicente Baz collaborates with scholars based in Spain, United States and Germany. David Vicente Baz's co-authors include Luis Paz‐Ares, Javier Salvador Bofill, Luis de la Cruz‐Merino, Jin‐Hyoung Kang, Enrique Grande Pulido, Manuel Cobo, Mariano Provencio, Jan P. van Meerbeeck, Xiuning Le and Young‐Chul Kim and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

David Vicente Baz

25 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Vicente Baz Spain	10	173	138	52	40	29	27	235
Silvana Acquafredda Italy	6	159 0.9×	94 0.7×	42 0.8×	43 1.1×	40 1.4×	8	237
Stephanie P.L. Saw Singapore	6	138 0.8×	166 1.2×	68 1.3×	25 0.6×	54 1.9×	14	278
Larry Leon United States	8	258 1.5×	232 1.7×	36 0.7×	25 0.6×	41 1.4×	14	316
Qing Chang China	7	239 1.4×	179 1.3×	55 1.1×	30 0.8×	32 1.1×	21	308
Farah Louise Lim United Kingdom	4	249 1.4×	159 1.2×	25 0.5×	56 1.4×	24 0.8×	7	287
Yuki Takeyasu Japan	8	169 1.0×	136 1.0×	29 0.6×	25 0.6×	33 1.1×	29	242
Carlos Mayo United States	9	164 0.9×	151 1.1×	75 1.4×	18 0.5×	41 1.4×	16	254
Grygorii Ursol United Kingdom	4	233 1.3×	143 1.0×	27 0.5×	54 1.4×	24 0.8×	6	268
Sara Fancelli Italy	9	197 1.1×	134 1.0×	103 2.0×	34 0.8×	58 2.0×	25	302
Ying Cheng China	8	211 1.2×	102 0.7×	64 1.2×	31 0.8×	33 1.1×	48	269

Countries citing papers authored by David Vicente Baz

Since Specialization

Citations

This map shows the geographic impact of David Vicente Baz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Vicente Baz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Vicente Baz more than expected).

Fields of papers citing papers by David Vicente Baz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Vicente Baz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Vicente Baz. The network helps show where David Vicente Baz may publish in the future.

Co-authorship network of co-authors of David Vicente Baz

This figure shows the co-authorship network connecting the top 25 collaborators of David Vicente Baz. A scholar is included among the top collaborators of David Vicente Baz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Vicente Baz. David Vicente Baz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Italiano, Antoine, Hossein Borghaei, Sanjay Popat, et al.. (2024). 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study. Immuno-Oncology Technology. 24. 100747–100747. 3 indexed citations

Pons‐Tostivint, Elvire, Isamu Okamoto, Jacob Sands, et al.. (2024). 1312P Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01. Annals of Oncology. 35. S835–S836.

Cappuzzo, Federico, Jyoti D. Patel, Byoung Chul Cho, et al.. (2024). 60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study. ESMO Open. 9. 102639–102639. 2 indexed citations

Cho, Byoung Chul, Rubén Cabanillas, David Vicente Baz, et al.. (2023). OA05.04 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study. Journal of Thoracic Oncology. 18(11). S54–S54. 6 indexed citations

Ahn, M-J., Aaron Lisberg, Luis Paz‐Ares, et al.. (2023). LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. Annals of Oncology. 34. S1305–S1306. 34 indexed citations

Lisberg, Aaron, Luis Paz‐Ares, Robin Cornelissen, et al.. (2023). 509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01. Annals of Oncology. 34. S1665–S1666. 11 indexed citations

Vokes, Everett E., F. Mornex, Ahmet Sezer, et al.. (2023). Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. Journal of Thoracic Oncology. 19(2). 285–296. 13 indexed citations

Lee, Siow Ming, Christian Schulz, Bei Han, et al.. (2022). LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen. Annals of Oncology. 33. S1418–S1419. 16 indexed citations

Le, Xiuning, Luis Paz‐Ares, Jan P. van Meerbeeck, et al.. (2022). Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx).. Journal of Clinical Oncology. 40(16_suppl). 9121–9121. 9 indexed citations

10.

Dowlati, Afshin, Sandrine Hiret, Achim Rittmeyer, et al.. (2022). An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS8600–TPS8600. 1 indexed citations

11.

Kowalski, Dariusz M., Alexander Luft, David Vicente Baz, et al.. (2022). 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 33. S993–S994. 8 indexed citations

12.

Andrić, Zoran, Gabriella Gálffy, Manuel Cobo, et al.. (2021). 103P First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 16(4). S753–S754. 3 indexed citations

13.

García‐Luna, Pedro Pablo, et al.. (2021). Analysis of nutritional interventions in the care process of oncological patients in Andalusia — the NOA project. Nutrición Hospitalaria. 38(4). 758–764. 2 indexed citations

14.

Le, Xiuning, Luis Paz‐Ares, Jan P. van Meerbeeck, et al.. (2021). Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp).. Journal of Clinical Oncology. 39(15_suppl). 9021–9021. 30 indexed citations

15.

Arriola, Edurne, Ramón García Gómez, Pilar Díz, et al.. (2018). Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 18(1). 106–106. 14 indexed citations

16.

Baz, David Vicente, et al.. (2018). 156P ASTRIS, a real-world study with osimertinib in patients with non-small cell lung cancer (NSCLC) EGFR T790M mutated: Characteristics and diagnostic methods used for patients included in Spain. Journal of Thoracic Oncology. 13(4). S93–S94. 2 indexed citations

17.

Murakami, Shuji, Mustafa Özgüroğlu, Augusto Villegas, et al.. (2017). PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC. Annals of Oncology. 28. x122–x122. 2 indexed citations

18.

Paz‐Ares, Luis, Augusto Villegas, Davey B. Daniel, et al.. (2017). PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC. Annals of Oncology. 28. v634–v634. 1 indexed citations

19.

Baz, David Vicente, et al.. (2005). Tumor de colisión. Adenocarcinoma y linfoma MALT gástrico sincrónicos. Medicina Clínica. 124(8). 318–319. 3 indexed citations

20.

Baz, David Vicente, et al.. (2001). Irinotecan-Induced Dysarthria. JNCI Journal of the National Cancer Institute. 93(18). 1419–1420. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact